Budiodarone tartrate

Cat. No.:	HY-14834A	
CAS No.:	478941-93-4	
Molecular Formula:	C ₃₁ H ₃₇ I ₂ NO ₁₁	
Molecular Weight:	853.43	
Target:	Potassium Channel; Sodium Channel; Calcium Channel	
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling	
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months: -20°C, 1 month (sealed storage, away from moisture)	

SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (117.17 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	1.1717 mL	5.8587 mL	11.7174 mL	
		5 mM	0.2343 mL	1.1717 mL	2.3435 mL	
		10 mM	0.1172 mL	0.5859 mL	1.1717 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.			
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1 mg/mL (1.17 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1 mg/mL (1.17 mM); Clear solution					
	 Add each solvent of Solubility: ≥ 1 mg/ 	one by one: 10% DMSO >> 90% cor mL (1.17 mM); Clear solution	n oil			

Description	Budiodarone (ATI-2042) tartrate is a chemical analogue of Amiodarone (HY-14187) with balanced, multiple cardiac ion channel (potassium, sodium and calcium channels) inhibiting activity. Budiodarone tartrate is an antiarrhythmic agent ^[1] .			
In Vitro	Budiodarone (ATI-2042) tartrate has a short plasma half-life (7 h) and a lower volume of distribution (13 L/kg) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES



[1]. Ezekowitz MD, et al. A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2012 Jun;34(1):1-9.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA